Tigermed, Fosun, Haisco and Sinopharm-CICC all scored exits as the oncology and metabolic disorder therapeutics went public in China.

China-based cancer and metabolic disorder drug developer Hinova Pharmaceuticals floated on Tuesday in an initial public offering sized at approximately RMB1.06bn ($166m), enabling corporates Tigermed, Fosun, Haisco and Sinopharm to exit, DealStreetAsia reported. The company issued nearly 24.8 million shares on Shanghai Stock Exchange’s Star Market, priced at RMB42.90 each, with Citic Securities lead underwriter…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.